Pulmatrix(PULM) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update Completed series of transactions with MannKind Corporation validating iSPERSE™ technology and extending projected cash runway into Q4 2026 $12.4 million in cash and cash equivalents at the end of Q2 2024, with an additional$1.4 million in restricted cash becoming unrestricted in August 2024 Pursuing strategic alternatives to further leverage iSPERSE™ and optimize the potential of PUR3100 Framingham, Mass., ...